Incremental Net Benefit and Incremental Cost-Effectiveness Ratio of COVID-19 Vaccination Campaigns: Systematic Review of Cost-Effectiveness Evidence

Overview

Journal Vaccines (Basel)

Date 2023 Feb 28

PMID 36851226

Authors

Giuseppe Santoli

Mario Cesare Nurchis

Giovanna Elisa Calabro

Gianfranco Damiani

Affiliations

Soon will be listed here.

Abstract

SARS-CoV-2 vaccination has been the most effective tool to prevent COVID-19, significantly reducing deaths and hospitalizations worldwide. Vaccination has played a huge role in bringing the COVID-19 pandemic under control, even as the inequitable distribution of vaccines still leaves several countries vulnerable. Therefore, organizing a mass vaccination campaign on a global scale is a priority to contain the virus spread. The aim of this systematic review was to assess whether COVID-19 vaccination campaigns are cost-effective with respect to no vaccination. A systematic literature search was conducted in the WHO COVID-19 Global literature database, PubMed, Web of Science, Embase, and Scopus from 2020 to 2022. Studies assessing the COVID-19 vaccination campaign cost-effectiveness over no vaccination were deemed eligible. The "Drummond's checklist" was adopted for quality assessment. A synthesis of the studies was performed through the "dominance ranking matrix tool". Overall, 10 studies were considered. COVID-19 vaccination was deemed cost-effective in each of them, and vaccination campaigns were found to be sustainable public health approaches to fight the health emergency. Providing economic evaluation data for mass vaccination is needed to support decision makers to make value-based and evidence-based decisions to ensure equitable access to vaccination and reduce the COVID-19 burden worldwide.

Citing Articles

Cost-effectiveness of preventive COVID-19 interventions: a systematic review and network meta-analysis of comparative economic evaluation studies based on real-world data.

Tang X, Sun S, Memedi M, Hiyoshi A, Montgomery S, Cao Y J Glob Health. 2025; 15:04017.

PMID: 39977668 PMC: 11842005. DOI: 10.7189/jogh.15.04017.

The Impact of Vaccination on COVID-19, Influenza, and Respiratory Syncytial Virus-Related Outcomes: A Narrative Review.

Debbag R, Rudin D, Ceddia F, Watkins J Infect Dis Ther. 2024; 14(Suppl 1):63-97.

PMID: 39739199 PMC: 11724835. DOI: 10.1007/s40121-024-01079-x.

Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Among Older Adults in Greece.

Gourzoulidis G, Tzanetakos C, Solakidi A, Markatis E, Detsis M, Mendes D Vaccines (Basel). 2024; 12(11).

PMID: 39591135 PMC: 11598676. DOI: 10.3390/vaccines12111232.

A systematic review and quality assessment of economic evaluations of kidney replacement therapies in end-stage kidney disease.

Nyokabi P, Youngkong S, Bagepally B, Okech T, Chaikledkaew U, Mckay G Sci Rep. 2024; 14(1):23018.

PMID: 39362958 PMC: 11450173. DOI: 10.1038/s41598-024-73735-8.

A health technology assessment of COVID-19 vaccination for Nigerian decision-makers: Identifying stakeholders and pathways to support evidence uptake.

Uzochukwu B, Okeke C, Shuaib F, Torres-Rueda S, Vassall A, Jit M Health Res Policy Syst. 2024; 22(1):73.

PMID: 38926716 PMC: 11210088. DOI: 10.1186/s12961-024-01158-y.

References

Thompson J, Wattam S . Estimating the impact of interventions against COVID-19: From lockdown to vaccination. PLoS One. 2021; 16(12):e0261330. PMC: 8683038. DOI: 10.1371/journal.pone.0261330. View

Willan A . Incremental net benefit in the analysis of economic data from clinical trials, with application to the CADET-Hp trial. Eur J Gastroenterol Hepatol. 2004; 16(6):543-9. DOI: 10.1097/00042737-200406000-00006. View

Scholz S, Weidemann F, Damm O, Ultsch B, Greiner W, Wichmann O . Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany. Value Health. 2021; 24(1):32-40. DOI: 10.1016/j.jval.2020.05.022. View

Kohli M, Maschio M, Becker D, Weinstein M . The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine. 2021; 39(7):1157-1164. PMC: 7832653. DOI: 10.1016/j.vaccine.2020.12.078. View

Deb P, Furceri D, Jimenez D, Kothari S, Ostry J, Tawk N . The effects of COVID-19 vaccines on economic activity. Swiss J Econ Stat. 2022; 158(1):3. PMC: 8753340. DOI: 10.1186/s41937-021-00082-0. View

Kirwin E, Rafferty E, Harback K, Round J, McCabe C . A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine. Pharmacoeconomics. 2021; 39(9):1059-1073. PMC: 8209775. DOI: 10.1007/s40273-021-01037-2. View

Sandmann F, Davies N, Vassall A, Edmunds W, Jit M . The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. Lancet Infect Dis. 2021; 21(7):962-974. PMC: 7972313. DOI: 10.1016/S1473-3099(21)00079-7. View

Syeed M, Ghule P, Le L, Veettil S, Horn E, Perdrizet J . Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies. Value Health. 2022; 26(4):598-611. DOI: 10.1016/j.jval.2022.10.006. View

van Riel D, de Wit E . Next-generation vaccine platforms for COVID-19. Nat Mater. 2020; 19(8):810-812. DOI: 10.1038/s41563-020-0746-0. View

10.

Bartsch S, Wedlock P, OShea K, Cox S, Strych U, Nuzzo J . Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination. J Infect Dis. 2021; 224(6):938-948. PMC: 8136017. DOI: 10.1093/infdis/jiab233. View

11.

Iino H, Hashiguchi M, Hori S . Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review. PLoS One. 2022; 17(4):e0266934. PMC: 9009631. DOI: 10.1371/journal.pone.0266934. View

12.

Sridhar S, Brokstad K, Cox R . Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines. Vaccines (Basel). 2015; 3(2):373-89. PMC: 4494344. DOI: 10.3390/vaccines3020373. View

13.

Majeed A, Pollock K, Hodes S, Papaluca M . Implementation of covid-19 vaccination in the United Kingdom. BMJ. 2022; 378:e070344. DOI: 10.1136/bmj-2022-070344. View

14.

Rafferty E, McDonald W, Osgood N, Doroshenko A, Farag M . What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model. Value Health. 2021; 24(1):50-60. DOI: 10.1016/j.jval.2020.10.004. View

15.

Padula W, Malaviya S, Reid N, Cohen B, Chingcuanco F, Ballreich J . Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis. J Med Econ. 2021; 24(1):1060-1069. PMC: 9897209. DOI: 10.1080/13696998.2021.1965732. View

16.

Franco-Paredes C . Transmissibility of SARS-CoV-2 among fully vaccinated individuals. Lancet Infect Dis. 2021; 22(1):16. PMC: 8694744. DOI: 10.1016/S1473-3099(21)00768-4. View

17.

Hoch J, Dewa C . A clinician's guide to correct cost-effectiveness analysis: think incremental not average. Can J Psychiatry. 2008; 53(4):267-74. DOI: 10.1177/070674370805300408. View

18.

Alves Fernandes R, Santos M, Magliano C, Tura B, Macedo L, Padila M . Cost Utility of Vaccination Against COVID-19 in Brazil. Value Health Reg Issues. 2022; 31:18-24. PMC: 8935121. DOI: 10.1016/j.vhri.2022.01.009. View

19.

Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J . COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022; 22(7):1002-1010. PMC: 8993156. DOI: 10.1016/S1473-3099(22)00146-3. View

20.

Doran C . Economic evaluation of interventions to treat opiate dependence : a review of the evidence. Pharmacoeconomics. 2008; 26(5):371-93. DOI: 10.2165/00019053-200826050-00003. View